0:16 24 November 2021
'Today's debut on WSE is hope for millions of patients': President of PolTREG
PolTREG, a company founded by medical innovators, made its debut on Tuesday, November 23, 2021, on the Warsaw Stock Exchange. It conducts worldwide pioneering research into cell therapies that can bring a breakthrough in the treatment of autoimmune diseases.
PolTREG is the twelfth entity to join the group of companies listed on the WSE this year and the tenth company from the biotechnology sector to be present on the Main Market.
At the beginning of November, PolTREG allocated the maximum number of 1,332,414 new shares in the public offering. The total value of the public offering amounted to approx. PLN 100 million gross, and the reduction rate in the retail tranche was 24.22 percent. The share price at today's opening of trading was set at PLN 75.
“Our efforts are focused on obtaining the capital necessary to continue clinical trials and – in the near future – to offer their results to patients around the world. Perhaps, when we meet here in five years, we will be able to talk about type I diabetes or multiple sclerosis as diseases of the past for which we have found a cure,” prof. Piotr Trzonkowski, president of the management board of PolTREG, argued.
